Publications by authors named "B W Ferrigno"
We report the transfer of H-atoms from a reduced polyoxovanadate alkoxide [OctN][VO(OH)(OMe)] concerted proton-electron transfer. Oxygen reduction is compared between bridging and terminal O-H bonds revealing similar mechanisms, providing new insight to design criteria for metal-oxide electrocatalysts that faciliate oxygen reduction by concerted-proton electron transfer.
View Article and Find Full Text PDFArticle Synopsis
- Autoimmune liver diseases (AILDs) like autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis show varied survival rates post-liver transplant (LT), influenced by factors such as disease severity and socio-economic conditions.
- Analyzing data from 13,702 AILD patients listed for LT from 2002 to 2021, the study focused on waitlist removal, patient survival, and graft survival, taking into account demographics, health conditions, and social factors.
- Findings revealed that lack of college education and public insurance increased waitlist removal and negatively affected both patient and graft survival, while unemployment had the most significant adverse effect on survival outcomes; U.S. citizenship status did not impact
Primary sclerosing cholangitis (PSC) is the leading indication of liver transplantation (LT) among autoimmune liver disease patients. There is a scarcity of studies comparing survival outcomes between living-donor liver transplants (LDLT)s and deceased-donor liver transplants (DDLTs) in this population. Using the United Network for Organ Sharing database, we compared 4679 DDLTs and 805 LDLTs.
View Article and Find Full Text PDFPrimary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics.
View Article and Find Full Text PDFGoals: We aim to summarize the current management of pruritus in primary biliary cholangitis (PBC) by evaluating the efficacy and safety of pharmacological therapies.
Background: Pruritus is a common symptom of PBC, and evidence regarding the most effective antipruritic agents available is lacking. New pharmacotherapy for PBC has shown promising antipruritic effects.